Safety of intravenous proteolytic enzymes (varizyme) in equine practice.

This research discusses the safety of administering intravenous proteolytic enzymes, specifically a combined formulation of streptokinase, streptodornase, and human plasminogen, in horses. The results indicated no adverse reactions in horses given only the enzyme combination, but there were temporary reactions observed in two cases where the enzymes were administered alongside the antibiotic chlortetracycline.

Overview of the Research

• The aim of this research was to explore the safety of intravenous proteolytic enzymes (specifically, a combination of streptokinase, streptodornase, and human plasminogen) in equine practice.
• The objective was to understand if there are any adverse reactions in horses when they are given these enzymes intravenously.

Study Design and Methodology

• The research involved the administration of the combined streptokinase, streptodornase, and human plasminogen to horses. The enzyme combination was given in either 125,000-unit or 375,000-unit doses.
• The researchers also studied the reaction of horses when they were given these enzymes in combination with the antibiotic chlortetracycline.

Research Results

• The findings from the study indicated that no horse experienced an adverse clinical reaction when they received the combined enzyme formulation in isolation
• However, in two instances where the enzyme combination was given alongside chlortetracycline, there were untoward reactions observed in the horses. Notably, these reactions were temporary and subsided without any additional treatment.

Conclusions and Implications

• The study showed that the intravenous administration of combined streptokinase, streptodornase, and human plasminogen seems to be safe for horses, as no adverse reactions were reported.
• The reactions noted in the cases where the antibiotics were co-administered suggest that caution might be needed when these enzymes are used in combination with other medications.